DoNatur GmbH

Company

    • Company type:
      • Research & Development
    • Year founded:
    • 1999
    • Employees (at the site):
    • 5
    • Turnover range:
    • <5m EUR
    • Products/services:
    • DoNatur GmbH develops new therapeutics with pure drug substances from medicinal plants. Isolation, structural disclose as well as the pharmacology and clinical investigation of the drug substances comprises the main competence of the company. DoNatur is in advanced development phase with the antirheumatic drug substance MCS-18 with successfully completed Phase II clinical study of MCS Injection in arthritis pain.

    • Core competencies:
    • DoNatur GmbH is skilled in isolation and structural characterization of novel drug substances from traditionally used medicinal plants. Main focus of the R&D activities of the company is the application of the novel drug substances in the therapy of pain and inflammatory overreaction of the immune systems.

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 20.59: Manufacture of other chemical products n.e.c.
      • 86.90: Other human health activities
      • 21.20: Manufacture of pharmaceutical preparations
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Franz Kerek (Mr.)
      - Management